PEGUNIGALSIDASE ALFA
Pegunigalsidase alfa 20 mg/10 mL injection, 10 mL vial
PEGUNIGALSIDASE ALFA (15483X)
15483X
Manner of administration:Injection
Restriction
Indication: Fabry disease
Treatment phase: Initial treatment
Restriction
Indication: Fabry disease
Treatment phase: Continuing treatment
Restriction
Indication: Fabry disease
Treatment phase: Grandfather arrangement (transition from LSDP-funded Fabry disease therapy)
Restriction
Indication: Fabry disease
Treatment phase: Switching from PBS-subsidised migalastat
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $2,891.64 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| ELFABRIO | |||||